title: A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options.
authors.affiliation: Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
authors.forename: Florian
authors.initials: F
authors.lastname: Eisner
authors.affiliation: Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
authors.forename: Martin
authors.initials: M
authors.lastname: Pichler
authors.affiliation: GLYCOTOPE GmbH, Berlin, Germany.
authors.forename: Steffen
authors.initials: S
authors.lastname: Goletz
authors.affiliation: Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
authors.forename: Herbert
authors.initials: H
authors.lastname: Stoeger
authors.affiliation: Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
authors.forename: Hellmut
authors.initials: H
authors.lastname: Samonigg
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016466:CHO Cells; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006224:Cricetinae; D003412:Cricetulus; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D012074:Remission Induction; D000068878:Trastuzumab / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
keywords: CANCER; COLORECTAL CANCER; MONOCLONAL ANTIBODY